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Low levels of basic fibroblast growth factor (bFGF) are
associated with a poor prognosis in human breast
carcinoma
R Colomer,l J Aparicio2, S Montero1, C Guzman', L Larrodera2 and H Cortes-Funes'
Divisions of 'Medical Oncology and 2Clinical Biochemistry, Hospital Universitario Doce de Octubre, Ctra de Andalucia Km. 5.4, 28041 Madrid, Spain
Summary It has been suggested that angiogenesis and angiogenic factors may be strong predictors of relapse in patients with breast
carcinoma. We measured the levels of the angiogenic peptide basic fibroblast growth factor (bFGF) in 140 breast tumour cytosols using an
immunoassay. There were no significant differences in bFGF levels between breast non-malignant lesions and primary carcinomas. In 124
cases with primary breast cancer, we observed an association of low bFGF levels (< 400 pg mg-') with increasing tumoursize (P= 0.023) and
stage of disease (P= 0.002). bFGF levels did not correlate with othervariables, including axillary nodes, hormone receptors, cathepsin D and
the serum tumour markers CA15.3 and CEA. With a median follow-up of 44.0 months, breast cancer patients with low levels of bFGF had a
significantly shorter disease-free survival (DFS) than patients with elevated bFGF (log-rank, P < 0.0001). In a multivariate analysis of DFS,
only bFGF, T-stage and histological grade showed statistical significance. In a parallel evaluation of circulating bFGF, we did not observe a
correlation between the serum and tissue bFGF levels in the 29 selected cases with matched determinations. Our results indicate that low
bFGF levels in breast carcinoma are an independent prognostic indicator of poor prognosis and disease recurrence.
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The prediction of the development of distant metastases in breast
carcinoma is a very relevant prognostic end point. Breast cancer
prognosis has relied traditionally on the evaluation of tumour size
and axillary node involvement. A substantial body ofexperimental
evidence supports the hypothesis that tumour angiogenesis is
fundamental for the progression and spread of solid tumours
(Weidner et al, 1991; Gasparini and Harris, 1995).
Several angiogenic peptides have been identified (Folkman and
Shing, 1992). One ofthese, basic fibroblast growth factor (bFGF),
is a heparin-binding protein that has been implicated in the growth
and metastases of a variety of solid cancers (Nanus et al, 1993;
Zimering et al, 1993).
In this study, we have investigated whether bFGF levels in
breast carcinoma cytosols correlated with prognosis and disease
relapse. We report that low levels of bFGF correlate with
increasing tumour size and stage of disease and that patients with
low bFGF have an unfavourable clinical course.
PATIENTS AND METHODS
Patients
We studied 140 unselected patients who underwent breast surgery
at our institution during the year 1992. The patients had breast
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carcinoma or a benign breast condition, and no other primary
cancer. Tumour stage was defined according to the International
Union Against Cancer classification, and the number of involved
axillary lymph nodes and histological grade was determined by
pathological examination.
Chemotherapy was administered to all patients with axillary
node involvement, in premenopausal patients with tumour size
> 1 cm and in post-menopausal patients with negative oestrogen
receptor (E1R). Tamoxifen was given to all patients with positive
ER. Radiation therapy was administered in cases with conserva-
tive surgery and in patients with four or more axillary nodes
involved.
Cases with primary breast cancer (stage I-III) were followed
post-operatively to detect disease relapse. Physical examinations
were performed at leastevery 3 months in all women. Relapse was
defined as the first documented evidence of new disease manifes-
tation in locoregional area, distant site, the contralateral breast or a
combination ofthese sites. Disease-free survival was calculated as
the period from surgery to the date of the first recurrence.
Although not an end point of the study, overall survival was also
recorded in patients with primary breast cancer.
Preparation of tumour extracts
Cytosol tumour extracts were prepared from frozen tumours in
10 mM Tris buffer pH 7.4, containing 1.5 mM ethylenediamine
tetraacetic, 10 mm monothioglycerol and 10 mM sodium molyb-
date. The oestrogen receptors and the progesterone receptors (PR)
were determined immediately. Tumour extract protein concentra-
tions were assayed using the Lowry method. Aliquots were stored
at -80°C until the measurement ofbFGF and cathepsin D.
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bFGF assay
The bFGF assay system (Amersham Biotrak) is based on a solid
phase ELISA that uses a highly specific monoclonal antibody for
FGF bound to the wells ofa microtitre plate, together with a poly-
clonal antibody to bFGF conjugated to horseradish peroxidase.
The Biotrak bFGF immunoassay contains recombinant human
bFGF, and it has been shown to quantitate accurately both the
natural human bFGF and the recombinant human bFGF. Cytosol
extracts were diluted to aprotein concentration of0.25 mg ml-1 and
the assays were performed in duplicate. The sensitivity ofthe assay
was 1 pg ml-l; this was determined by adding two standard devia-
tions to the mean optical density often zero-standard replicates and
by calculating the corresponding concentration from the standard
curve. The intra- and interassay coefficients of variation (n = 8)
were 5.0% and 7.1%, at about 213.3 pg ml-1 of control, respec-
tively. The linearity of the assay (r = 0.99) was determined using
biological samples with high concentrations ofbFGF diluted with
the calibrator diluent. The bFGF value was normalized against
cytosol protein content and expressed in pg mg-' ofprotein.
ER, PR and cathepsin D assays
The oestrogen receptor (ER) and the progesterone receptor (PR)
were assayed using an enzyme immunoassay kit (Abbott).
Tumours were classified as ER or PR positive ifthe content ofER
and PR was greater than 10 and 20 fmol mg-' protein respectively.
For cathepsin D, the immunoradiometric assay (ELSA-Cath-D
kit, CIS Bio-industries) used in this study is aquantitative determi-
nation oftotal cathepsin D (52K, 38K, 34Kproteins) in the tumour
extracts. Samples were diluted to 1:80 and were assayed in dupli-
cate. Results are expressed in pmol mg-1 oftotal protein. We used
the cut-offpoint indicated by the manufacturer (70 pmol mg-').
Serum determinations
Early-morning-fasting blood samples were obtained frompatients.
Blood samples were centrifuged, and the serum was frozen and
assayed within 1 week forCA15.3 and CEA. Aliquots were stored
at - 800C until required for the bFGF assay.
bFGF content of29 serum samples was analysed with the assay
system previously described (Amersham Biotrak). The interassay
coefficient was 3.1%. The results are expressed in pg ml-'.
The tumour markers CA15.3 and CEA were determined using
two enzyme immunological tests (ELISA) of one and two steps
respectively. These sandwich assays use streptavidin technology
and are automated in a ES-300 analyser (Boehringer Mannheim).
The normal value of CA15.3 is lower than 30 U ml-', and the
normal range ofCEA is less than 5 ng ml-'.
Statistical analysis
To identify the optimal cut-off point for bFGF, we used the
minimum P-value method, in which the statistical significance of
different arbitrary cut-offpoints is tested and the cut-offpoint that
shows the minimum P-value is selected. To confirm the statistical
value of bFGF, the study variable was treated as a continuous
covariate in a Cox model, as proposed by Altman et al (1994).
Differences in mean values were assessed with the Kruskal-Wallis
test. The chi-square test was used to test for association between
bFGF levels and qualitative parameters. The Kaplan and Meier
Table 1 Characteristics of cases with breast carcinoma
Characteristic
Median age (range)
Menopausal status
Pre
Peri
Post
Tumour size
Ti
T2
T3
T4
No. of positive axillary lymph nodes
0
1-3
3-9
> 10
UICC Stage
11
Histological grade
1
2
3
Oestrogen receptor positive
Progesterone receptor positive
Cathepsin D positive
CA 15.3 positive
CEA positive
Treatment
Adjuvant systemic
Local only
Recurrences
Deaths
Number of cases (%)
57 (29-83) years
47 (38)
8 (7)
69 (55)
49 (39)
55 (44)
12 (10)
8 (6)
57 (47)
42 (34)
15 (12)
8 (7)
31 (25)
72 (59)
19 (16)
16 (15)
49 (46)
42 (39)
99 (82)
77 (63)
17 (14)
12 (11)
7 (6)
111 (89)
13 (11)
28 (23)
19 (15)
Cut-off levels: oestrogen receptor, 10 fmol mg-1; progesterone receptor,
20 fmol mg-'; cathepsin D, 70 pmol mg-'; CA 15.3, 30 U ml-1; CEA,
5 ng ml-'. Local treatment included surgery with or without radiation therapy.
Table 2 bFGF protein levels in breast tumours
bFGF level (pg mg-')
n Mean ± s.d. 95% Cl P-value
Benign breast lesions 16 658.2±417.0 436-880
Breast carcinoma total 124 839.2 ± 655.2 722-955 NSa
Stage 31 1016.3 ± 790 726-1306
Stage II 72 856.5 ± 616 711-1101
Stage 1I1 19 509.7 ± 457 289-730 0.004b
aBenign vs carcinoma. bStage 1 vs stage 11 vs stage Ill. Analysis of benign
lesions vs individual carcinoma stage 1, II or IlIl showed that the differences
observed are not significant.
estimate was used to calculate disease-free and overall survival,
and the Cox-Mantel version ofthe log-rank test was used to make
comparisons. Correlations were calculated by the Spearman test.
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Table 3 Correlation of tumour bFGF content with other variables
Variable No. of patients (%) with low P-value
bFGF (< 400 pg mg-1)
ci.
0.01
0.001
200 300 400 500 700 900 1000 1100
bFGF cut-off level (pg mg-1)
Figure 1 Basic fibroblast growth factor prognostic cut-off in breast
carcinoma. The minimum P-value method was used for the selection of the
optimal bFGF cut-off related to disease-free survival. For further evaluation
400 pg mg-1 protein was selected
RESULTS
The study group consisted of 124 primary breast carcinomas (stage
I-III) from 122 patients (two cases had bilateral cancer). The char-
acteristics of the patients in the study are listed in Table 1.
Histology was infiltrating ductal carcinoma in 116 cases, infil-
trating lobular carcinoma in seven cases and other in one case. The
median age ofthis group was 57.0 (± 14.1) years. The characteris-
tics ofthe patients with breast carcinoma are detailed in Table 1. A
second group was formed by 16 benign breast conditions, which
included fibrocystic disease (six cases), fibroadenoma (three
cases), fibrocystic disease plus fibroadenoma (two cases), phyl-
lodes tumour (two cases), infiltrating epitheliosis (one case),
fibroglandular nodule (one case) and fibrosis (one case); median
age was 54.1 (± 10.8) years.
bFGF was detectable in all cases (range 28-4408 pg mg-').
bFGF mean levels in patients with breast carcinoma were not
significantly different to those of patients with benign breast
diseases (Table 2). We observed a significant trend for breast
cancer patients with more advanced stage to have lower levels of
bFGF (P = 0.004, Table 2).
Menopausal status
Pre
Peri
Post
Tumour size
Ti
T2
T3
T4
No. of positive axillary
lymph nodes
0
>1
UICC Stage
I
Histological grade
1
2
3
Oestrogen receptor
+
Progesterone receptor
+
Cathepsin D
+
CA 15.3
+
CEA
+
Treatment
Systemic
Local only
13 (28)
3 (37)
15 (22)
47
8
69
49
55
12
8
7 (14)
16 (29)
3 (25)
5 (62)
13 (23)
17 (26)
57
65
31
72
19
16
49
42
99
22
77
45
17
107
12
102
7
104
111
13
0.49
0.66
3 (10)
17 (23)
10 (53)
4 (25)
11 (22)
13 (31) 0.65
24 (24)
6 (27)
14 (18)
15 (33)
2 (12)
29 (27)
0.76
0.057
0.17
0.45
0.55
0.39
4 (33)
24 (23)
1 (14)
25(24)
29 (26)
2 (15)
Cut-off levels and stratification of variables as in Table 2, except for the
number of positive axillary lymph nodes (0 vs 2 1).
Cut-off point determination
When the median follow-up reached 22 months, we tested
different cut-off values for bFGF, between 200 and 1100 pg mg-'
protein, calculating their P-values in a disease-free survival
analysis. The best discrimination into two groups in the series was
obtained with the cut-off value of 400 pg mg-'. The P-value for
this cut-off point was 0.0085 (Figure 1). The numbers of patients
with bFGF values above each of the cut-off points 200, 250, 300,
350, 400, 450, 500, 600, 700, 800, 900, 1000 and 1100 pg mg-'
were, respectively, 119, 110, 107, 104, 94, 90, 83, 70, 60, 50, 46,
41, 37, 36 and 34. When bFGF was evaluated as a continuous vari-
able in a Cox analysis, a P-value of 0.023 was observed, which
confirmed the prognostic value ofthe variable.
Of the 124 patients with primary breast carcinoma, 93 (75%)
had elevated bFGF levels and 31 (25%) had low bFGF, while 69%
of cases with non-malignant breast conditions had elevated bFGF.
We observed no statistical difference in the bFGF positivity
between these two groups.
bFGF and other prognostic parameters
bFGF levels correlated inversely with tumour size and stage in
primary breast carcinomas. Larger tumours had a tendency to
show lower bFGF levels: 62% of T4 carcinomas had low bFGF
levels, as opposed to 25% of T3, 29% ofT2 and 14% ofTI carci-
nomas. This trend was significant (P = 0.023). Similarly, low
bFGF levels were associated with increasing disease stage: low
bFGF was observed in 53% of patients with stage III; 23% with
stage II and 10% with stage I (P = 0.002). We observed no associ-
ation of bFGF with menopausal status, axillary lymph node status
(0 vs 2 1 nodes), histological grade, hormone receptors, cathepsin
D, CA15.3, CEA or treatment administered (Table 3).
British Journal ofCancer (1997) 76(9), 1215-1220
0.023
0.002
0 CancerResearch Campaign 19971218 R Colomer etal
Table 4 Univariate and multivariate analysis of disease-free survival in
breast carcinoma stage I-l1l
P-value
Parameter Univariate Multivariate
bFGF 0.0000 0.0016
Tumour size 0.0000 0.0013
Histological grade 0.0000 0.0162
Lymph node status 0.0046 0.0587
Stage of disease 0.0000 -
Oestrogen receptor 0.0000 0.23
Progesterone receptor 0.0000 -
CA 15.3 0.02 -
Cathepsin D status 0.17
CEA 0.24 -
Menopausal status 0.43
Treatment 0.82
Cut-off levels and stratification of variables as in Table 3.
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Figure 3 Correlation of bFGF values in matched tissue and serum samples.
No correlation existed when matched samples from the same patients were
compared
bFGF levels, menopausal status and treatment did not show an associa-
tion with DFS. The Kaplan-Meier estimation ofDFS according to
93 91 85 74 18 bFGF levels is shown in Figure 2. To perform a multivariate
analysis, we took into account that the number ofevents was rela-
1.00 - - - tively few, and we selected the variables that were highly signifi-
--, cant in the univariate analysis: tumour size, histological grade,
075 lymph node status, oestrogen receptor status and bFGF status 0.75 t)_ (stage of disease and progesterone receptor status were not
included as they have a known association with T and N, and
0.50 oestrogen receptor status respectively). Only three ofthe variables
considered retained statistical significance: bFGF (P = 0.0016),
tumour size (P = 0.0014) and histological grade (P = 0.0162). The
0.25 fact that the lymph node status did not retain its prognostic signif-
icance in the multivariate analysis may reflect the routine use of
nodal status in our department as a selection of the intensity of
0.00 treatments.
0 12 24 36 48 60 Although not an end point in our study, we evaluated overall
Months survival in the patients with non-metastatic breast cancer. In a
,e 2 Disease-free survival in patients with breast carcinoma. A univariate analysis, tumour size (P = 0.0001), disease stage (P =
n-Meier plot shows that patients with low bFGF (-) had an adverse 0.0002), bFGF (P = 0.02), CA 15.3 (P = 0.02), histological grade
iosis compared with patients with elevated bFGF --- -). The difference (P = 0.03) and progesterone receptor (P =0.03) showed an associ-
;ignificant using the log-rank test. P= 0.0001
ation with overall survival. In a multivariate analysis, however,
tumour size was the only variable retaining statistical significance
(P = 0.0001).
Survival analysis
With a median follow-up of 44.0 months (range 9.9-58.1), 28
patients have relapsed and 19 have died. Relapses were distant in
18 patients, locoregional in nine patients and both distant and
locoregional in one case. Relapsing patients presented low bFGF
levels more frequently than non-recurring cases (54% vs 17%,
P = 0.0001). This significance was maintained when we analysed
separately distant relapses (47% vs 21%, P = 0.01) or locoregional
relapses (70% vs 21%, P = 0.0006). The patients who died during
the follow-up period showed low levels of bFGF more frequently
than the patients who remained alive (42% vs 22%, P = 0.06).
Univariate disease-free survival was analysed using the log-
rank test. Low bFGF levels, negative ER and PR, and increasing
tumour size, histological grade, lymph node status, disease stage
and CA 15.3 levels showed a significant association with DFS in
patients with primary breast cancer (Table 4). Cathepsin D, CEA
Circulating bFGF and correlation with tissue bFGF
We determined the levels ofcirculating bFGF in selected matched
cases, when serum samples were available (29 cases). This
subgroup was representative ofthe whole series: the proportion of
low tumour bFGF was 23% in the 29 cases, which is similar to the
overall percentage. The mean levels of serum bFGF were
19.4 ± 28.8 pg ml-1 (range 0-146 pg ml-'). Using 5 pg ml-' as a
cut-off, 16 patients showed elevated levels of bFGF and 13
showed low levels. We performed a correlation of tissue and
serum bFGF levels of patients (Figure 3). Serum bFGF did not
show a correlation with tissue bFGF (r2 = 0.0008, P = 0.86), indi-
cating that the variables are not associated. Although the number
of determinations was small, we performed an analysis of DFS in
relation with serum bFGF levels and did not observe an associa-
tion between circulating bFGF and DFS (log-rank, P = 0.81).
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DISCUSSION
bFGF is an angiogenic peptide that has been postulated to enhance
the growth ofprimary tumours and their metastases by stimulating
the growth of capillary endothelial cells in the tumour (Kandel et
al, 1991). We report the first evaluation of bFGF protein levels in
breast carcinoma cytosols, in relation to the prognosis and the
clinical course.
We did not observe significant differences in bFGF protein in
benign or malignant breast tissue cytosols. Other authors, evalu-
ating bFGF mRNA, found that breast carcinomas had lower bFGF
than breast non-malignant tissue (Luqmani et al, 1992; Anandappa
et al, 1994). This may reflect a selection of the cases with carci-
noma. We observed a significant trend for breast carcinomas to
have lower levels ofbFGF with more advanced stages, indicating
that bFGF is associated with earlier stages ofbreast carcinoma.
To define the normal cut-offforbFGF, we used the minimum P-
value method and found that 400 pg mg-' provided the best
discriminative value in a DFS analysis. At this point, we observed
that the carcinomas with low bFGF content exhibited a markedly
worse prognosis than the tumours with elevated bFGF. This was
not because of the selection of a particular cut-off, as alternative
cut-offs were explored up to 1100 pg mg', a value that was
reached only by 26% ofthe cases, and a progressive loss ofsignif-
icance was clearly seen. On the other hand, the distribution of
values in our series is similar to that reported by Anandappa et al
(1994), who evaluated bFGF mRNA in 102 breast cancers. About
30% of their carcinomas had bFGF levels that were undetectable,
which is similar to our 25% ofcases with low bFGF.
When bFGF was correlated with clinical and analytical vari-
ables in breast carcinoma, it showed significant associations with
tumour size and stage only. In our study, lower bFGF levels were
observed in cases with larger tumours and more advanced stage.
More importantly, low bFGF levels were significantly associated
with an elevated incidence of relapse: low bFGF was observed in
54% ofthe patients who recurred, in contrast with 17% in patients
not recurring. It is remarkable that there is the absence of correla-
tion of bFGF with the extent of axillary node involvement in our
series, which would argue against a direct role of tumour bFGF in
the process ofmetastasis.
The finding of lower levels ofbFGF in the cytosol ofthe carci-
nomas with worse prognosis induced us to test the levels ofcircu-
lating bFGF in 29 matched samples of tumour and serum. We did
not observe a correlation between tumour and circulating bFGF.
Other authors have evaluated circulating bFGF patients with breast
carcinoma, although never in matched samples. Takei et al (1981)
found elevated levels ofbFGF in 76% of40 breast cancer patients,
but in only 26% of controls. There were not clear differences in
serum bFGF by stage of breast carcinoma. Sliutz et al (1995)
showed preliminarily in 20 patients with breast carcinoma that
elevated preoperative serum bFGF induced a non-significant trend
to a poorer disease-free survival. The above data indicate that
circulating bFGF may be an adverse prognostic factor in patients
with breast cancer. In our limited series, however, we did not
observe an association between serum bFGF levels and DFS. In
addition, our correlation data strongly suggest that circulating
bFGF in patients with breast carcinoma is produced by sources
other than the primary breast carcinomas.
The association that we observed between low tumour bFGF
and adverse prognosis challenges the presumed role ofbFGF in the
angiogenesis-related spread of breast carcinoma. Our results,
however, are supported by other sets of data. First, it has been
reported that there is no direct relationship between the levels of
expression of bFGF mRNA and the vascular density in breast
cancers, indicating that the importance ofbFGF in angiogenesis is
not related to a simple quantitative relationship with blood vessels
(Winstanley et al, 1994). Second, the role ofbFGF in the dissemi-
nation and growth of breast cancer has been questioned in two
recent transfection studies. Davies et al (1996) showed that the
overexpression of the bFGF gene in rat mammary epithelial cells
did not confer metastatic properties in vivo, and Finnigan et al
(1995) have reported that overexpression of the bFGF gene in
MCF7 human breast carcinoma cells induced an inhibition of
growth in vitro. bFGF binds and activates high-affinity receptors,
butlow-affinity heparan sulphate receptors that sequesterbFGF are
also important to determine the biological activity ofbFGF. Davies
et al (1996) have suggested that the contribution of bFGF to the
metastatic potential of cells may not rely on the expression of the
growth factor itself, but also on an alteration to the bFGF dual-
receptor system. Third, some immunohistochemical studies have
shown that the bFGF protein and mRNA that is found in breast
tissue extracts is not produced by the epithelial cells. bFGF has
been almost exclusively localized in the myoepithelial cells of the
benign breast and breast carcinoma (Gomm et al, 1991; Ke et al,
1993). Importantly, it has also been shown that the breast myoep-
ithelial cells are progressively lost when breast carcinoma becomes
more invasive (Guelstein et al, 1993). Therefore, our observation
that breast carcinomas with more adverse prognosis have lower
levels ofbFGF is consistent with the loss of myoepithelial cells in
the more invasive carcinomas. Finally, the preliminary results of
other investigators show that, in agreement with our bFGF protein
data, low bFGF mRNA levels in breast carcinoma extracts are
correlated with an adverse prognosis (Coombes et al, 1994).
The results of our study suggest that bFGF may play a role
different to that postulated in the metastatic process of human
breast carcinoma. The adverse prognostic value of low bFGF
levels in breast carcinoma may have relevant biological and clin-
ical implications. The prognostic significance ofcytosol bFGF, as
well as the particular cut-off point that we chose, has to be
validated using an independent series. Further studies with bFGF
should run parallel with the immunohistochemical determination
ofmyoepithelial cells and microvessel densities.
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